Skip to main content

EYEN

Stock
Health Care
Biotechnology

Performance overview

EYEN Price
Price Chart

Forward-looking statistics

Beta
1.00
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees50
Market cap$40.9M

Fundamentals

Enterprise value$37.1M
Revenue$67.1K
Revenue per employee
Profit margin-6749.50%
Debt to equity-1.15

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$42.65
Dividend per share
Revenue per share$0.05
Avg trading volume (30 day)$115M
Avg trading volume (10 day)$137M
Put-call ratio

Macro factor sensitivity

Growth+1.1
Credit+5.9
Liquidity-0.3
Inflation-0.8
Commodities-0.6
Interest Rates-2.2

Valuation

Dividend yield0.00%
PEG Ratio-29.85
Price to sales1204.11
P/E Ratio-29.85
Enterprise Value to Revenue553.73
Price to book-3.24

Upcoming events

Next earnings dayMay 20, 2025
Next dividend day
Ex. dividend day

News

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.

Zacks Investment Research (November 18, 2024)
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia.

Benzinga (November 15, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free